{"url_path":"/sec/bold/8-k/2026-06-23/item-3-02","section_key":"item-3-02","section_title":"Item 3.02 Unregistered Sales of Equity Securities.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1782303/0001193125-26-278570-index.html","accession_number":"0001193125-26-278570","cik":"0001782303","ticker":"BOLD","issuer_name":"Boundless Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1782303/0001193125-26-278570-index.html","primary_entity_key":"0001782303","primary_entity_name":"Boundless Bio, Inc."},"word_count":144,"has_tables":true,"body_markdown":"Item 3.02 Unregistered Sales of Equity Securities.\n\nTo the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.\n\nThe shares of Serapha capital stock to be issued in the Pre-Closing Financing will be issued in private placements exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the Securities Act), and/or Regulation D promulgated thereunder, because the offer and sale of such securities does not involve a “public offering” as defined in Section 4(a)(2) of the Securities Act, and other applicable requirements were met. Neither this Current Report on Form 8-K nor any of the exhibits attached hereto is an offer to sell or the solicitation of an offer to buy the shares of Serapha capital stock or any other securities of Boundless Bio or Serapha."}